Clinical trials: Deglutition Disorder
Gastroesophageal Reflux
A Pharmacokinetic and Relative Bioavailability Study With Rabeprazole Sodium in Healthy Adult Volunteers
The purpose of the study is to evaluate and compare the pharmacokinetics (blood levels) of 2 different formulations, assess the effect of food on the pharmacokinetics and assess safety of rabeprazole sodium in healthy volunteers.
- Trial name
- NCT01101646
- Testing
- rabeprazole sodium
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
GERD
EndoStim Patient Registry
To provide a research tool enabling physicians to monitor long term clinical outcomes for patients undergoing gastroesophageal reflux disease (GERD) treatment with EndoStim LES Stimulation System.
- Trial name
- RESTORE (NCT02441400)
- Testing
- EndoStim LES Stimulation System
- Where
- 30 sites in Argentina, Austria and 5 more
- Volunteers
- 350 people
- Sponsor
- EndoStim Inc.
Gastroesophageal Reflux Disease (GERD), Reflux, Gastroesophageal
An Investigation of the EndoStim® Lower Esophageal Sphincter (LES) Stimulation System for the Treatment of Reflux
The purpose of this investigation is to demonstrate the safety and effectiveness of Lower Esophageal Sphincter (LES) Stimulation System in treating gastroesophageal reflux disease (GERD).
- Conditions
- Gastroesophageal Reflux Disease (GERD), Reflux, Gastroesophageal, Gastroesophageal Reflux, Acid Reflux
- Trial name
- NCT02749071
- Testing
- Laparoscopic implantation surgery with or without crural repair, EndoStim stimulation for first six months of study, EndoStim stimulation from Month 6 thru end of study
- Where
- 21 sites in United States, Belgium and 2 more
- Volunteers
- 161 people
- Sponsor
- EndoStim Inc.
Heartburn, Gastroesophageal Reflux Disease
Study Comparing Esomeprazole Magnesium 40mg Once Daily Versus Lansoprazole 30 mg Twice Daily in Symptom Control of Subjects With Persistent Gastrooesophageal Reflux Disease (GERD)
A double-blind study comparing Esomeprazole Magnesium 40 mg once daily and Lansoprazole 30 mg twice daily to control the symptoms in patients with gastroesophageal reflux disease (GERD) with continued heartburn symptoms with a…
- Trial name
- NCT00637845
- Testing
- Esomeprazole Magnesium, Lansoprazole
- Volunteers
- 248 people
- Sponsor
- AstraZeneca
Gastroesophageal Reflux Disease
Efficacy And Safety Of PF-00885706 For The Relief Of Symptoms In Subjects With Gastro-esophageal Reflux Disease (GERD)
To understand the dose-response characteristics of PF-00885706 for efficacy in terms of symptomatic relief when used as add-on treatment to esomeprazole 20mg (standard proton pump inhibitor [PPI] treatment), in subjects with…
- Trial name
- NCT00730665
- Testing
- PF-00885706, Esomeprazole
- Where
- 38 sites in Belgium, Brazil and 5 more
- Volunteers
- 81 people
- Sponsor
- Pfizer
Gastroesophageal Reflux Disease (GERD)
Rabeprazole Extended-Release, 50 mg, Versus Esomeprazole, 40 mg, for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)
The purpose of this study is to investigate the efficacy (ie, healing and symptom relief) and safety of Rabeprazole Extended-Release (RAB ER) 50 mg versus Esomeprazole (ESO) 40 mg for the treatment of moderate to severe erosive…
- Trial name
- NCT00658775
- Testing
- Rabeprazole sodium, Esomeprazole
- Where
- 83 sites in United States, Argentina and 12 more
- Volunteers
- 1,069 people
- Sponsor
- Eisai Inc.
Gastroesophageal Reflux
Tolerability Study of a Novel Microbiome Therapeutic in Subjects With Gastroesophageal Reflux Disease
This is a remote study. No office visits required. The purpose and efficacy endpoint of this study is to assess whether GERD patients tolerate ISOT-101.
- Trial name
- NCT04491734
- Testing
- maltosyl-isomalto-oligosaccharides (MIMO)
- Where
- United States
- Volunteers
- 156 people
- Sponsor
- ISOThrive Inc.
Gastro Esophageal Reflux
Effect of a Combination Oral Formulation of Hyaluronic Acid, Chondroitin Sulphate and Magnesium Trisilicate in Patients With Gastro-Esophageal Reflux Disease Not Fully Satisfied With Their Treatment
This is a post-market, multi-center, double-blind, placebo-controlled, randomized, cross-over study with GERDOff Plus added on top of the current PPI treatment in patients with GERD.
- Trial name
- NCT04202692
- Testing
- Hyaluronic acid with chondroitin sulphate and magnesium trisilicate, 1100 mg melt in mouth tablet
- Where
- 2 sites in Germany
- Volunteers
- 40 people
- Sponsor
- SOFAR S.p.A.
Symptomatic Gastroesophageal Reflux Disease (sGERD)
Comparing the Efficacy, Safety, and Tolerability of Rabeprazole ER 50 mg With Placebo in Subjects With Symptomatic Gastroesophageal Reflux Disease (sGERD)
The purpose of this study is to compare the efficacy, safety and tolerability of rabeprazole extended release (ER) 50 mg with placebo in subjects with symptomatic gastroesophageal reflux disease (sGERD).
- Trial name
- NCT00911534
- Testing
- rabeprazole sodium
- Where
- 98 sites in United States
- Volunteers
- 305 people
- Sponsor
- Eisai Inc.
Feeding Tube, Dysphagia
Safety and Usability Evaluation of the Fidmi Low-Profile Enteral Feeding Device
A First In Human Usability Open Label trial will be performed using the Fidmi Feeding device on 20 adult patients with a need for enteral feeding.
- Trial name
- Fidmi (NCT03007511)
- Testing
- Fidmi enhanced enteral feeding device
- Where
- 2 sites in Israel
- Volunteers
- 20 people
- Sponsor
- Fidmi Medical
Healthy Volunteers
Single-dose and Multiple-dose X842 Phase 1 Study
The purpose of this study is to evaluate the safety and tolerability of X842 after administration of single and multiple doses in healthy subjects
- Trial name
- NCT04293965
- Testing
- Single ascending dose of X842, Multiple ascending dose of X842, Food Effect
- Where
- China
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Jiangsu Sinorda Biomedicine Co., Ltd
GERD
An Open-Label Study of Once-Daily Oral Administration of Esomeprazole 40 mg in Patients With Symptoms of Gastroesophageal Reflux Disease (GERD)
The purpose of this study is to evaluate whether there is a difference in proportion of patients with resolution of heartburn and other symptoms related to gastroesophageal reflux disease (GERD) after four weeks of treatment with…
- Trial name
- NCT00242736
- Testing
- Esomeprazole
- Where
- 25 sites in United States
- Volunteers
- 350 people
- Sponsor
- AstraZeneca
Gastroesophageal Reflux, Heartburn
A Study of Efficacy and Safety of "On-demand" Maintenance Therapy With Rabeprazole in Patients With Non-erosive Reflux Disease (NERD)
The purpose of this study is to assess the efficacy and safety of long-term, "on-demand" maintenance therapy with rabeprazole in patients with non-erosive reflux disease (NERD).
- Trial name
- NCT00236392
- Testing
- rabeprazole
- Volunteers
- 422 people
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
Achalasia
Study of IW-1701, A Stimulator of Soluble Guanylate Cyclase (sGC), in Patients With Type I or II Achalasia
The objectives of this study are as follows: In participants with primary Type I or II achalasia, following a single 5-mg dose of olinciguat (IW-1701), To assess the safety and tolerability To determine the effects on measures of…
- Trial name
- NCT02931565
- Testing
- Olinciguat
- Where
- 5 sites in United States
- Volunteers
- 9 people
- Sponsor
- Cyclerion Therapeutics
GERD
Study of the NDO Endoscopic Plication System For the Treatment of Symptomatic Gastroesophageal Reflux Disease
The purpose of this prospective, multicenter study was to evaluate the safety and efficacy of endoscopic full-thickness plication for the treatment of symptomatic gastroesophageal reflux.
- Trial name
- NCT00587522
- Testing
- NDO Full-thickness Plicator
- Where
- 7 sites in United States, Canada
- Volunteers
- 64 people
- Sponsor
- NDO Surgical, Inc.
Mitral Valve (MV) Regurgitation
ACCESS-Europe A Two-Phase Observational Study of the MitraClip® System in Europe
The MitraClip System enables the European physicians an alternative therapeutic option for patients with mitral regurgitation (MR).
- Trial name
- ACCESS-EU (NCT01288976)
- Testing
- MitraClip, Medical Management, Mitral Valve Surgery
- Where
- Germany
- Volunteers
- 721 people
- Sponsor
- Abbott Medical Devices
GERD (Gastroesophageal Reflux Disease)
A Study Comparing the Effect and Safety of Linaprazan Glurate to Lansoprazole in Maintenance of Healing in Participants With Healed Erosive Esophagitis (EE) Due to Gastroesophageal Reflux Disease (GERD)
The goal of this clinical trial is to investigate how well linaprazan glurate can maintain healed erosive esophagitis (EE) caused by GERD in participants who have participated in a prior healing trial, compared to lansoprazole…
- Trial name
- NCT07313774
- Testing
- Linaprazan glurate - High dose, Linaprazan glurate - Low dose, Lansoprazole - Marketed approved dose
- Sponsor
- Cinclus Pharma Holding AB
Gastroesophageal Reflux Disease
Effects of AFQ056 and Baclofen on Meal-Induced Gastroesophageal Reflux
This study will assess the safety and tolerability of oral single dose applications of AFQ056 in GERD patients.
- Trial name
- NCT00414856
- Testing
- AFQ056
- Where
- 4 sites in Belgium, France and 2 more
- Volunteers
- 34 people
- Sponsor
- Novartis
Mitral Valve (MV) Regurgitation
A Prospective, Multicenter, Single-Arm Study to Support the Clinical Evidence Base for MRace as a Treatment Option for FMR Patients With Complex M-TEER Anatomies (FR)
A pilot study to evaluate the safety and performance of the MRace System to treat severe mitral regurgitation and to gather data on its performance thereby providing guidance for future clinical development.
- Trial name
- ACCESS-MR (FR) (NCT07757607)
- Testing
- Transcatheter mitral valve repair (MRace Implant and Delivery System)
- Volunteers
- 20 people
- Sponsor
- Polares Medical SA
Gastroesophageal Reflux Disease
Diagnosis and Response to Treatment Using a Reliable Gastroesophageal Reflux Disease (GERD) Questionnaire: An In Clinical Practice Study
The purpose of the study is to determine the applicability and utility of Gerd Q in the diagnosis of GERD and in the assessment of treatment response.
- Trial name
- GQS (NCT00963144)
- Where
- 2 sites in Malaysia
- Volunteers
- 250 people
- Sponsor
- AstraZeneca